Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104/AK112 in Combination With TT-00420 in Advanced Hepatocellular Carcinoma
NCT07052253Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tinengotinib, cadonilimab, ivonescimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Jul 2025; status: recruiting.
02
Drugs
tinengotinibcadonilimabivonescimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07052253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052253.